Beam Therapeutics Appoints Carole Ho, M.D., to Board of Directors
Cambridge, Mass. – Beam Therapeutics, a biotechnology company developing precision...
The human genome is made up of billions of nucleobases, or “bases,” represented by the letters A, G, T, and C. Beam’s base editing technology can precisely target and make specific edits to a single base in DNA or RNA, without cutting or disrupting the gene. Base editors have the potential to repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. Beam is committed to developing base editors as a new class of precision genetic medicines that can treat or cure diseases affecting patients’ lives.
Starting with our founders and funders, we’re building a world-class team to develop precision genetic medicines through DNA and RNA base editing. Join us.
Beam seeks an experienced scientist to help us advance our New Opportunities programs, including discovering and validating the technical feasibilityRead More
This position will contribute to the analytical development activities supporting all Beam platforms (non-viral and viral). The candidate should haveRead More
Beam is looking for a highly motivated and experienced Research Associate to support our RNA editing & Novel CRISPR nucleasesRead More
26 Landsdowne Street
Cambridge, MA 02139